Research finds drug prices increased without adding new clinical benefits
The net prices of five drugs included in a new study from the Institute for Clinical and Economic Review increased without clinical justification in 2023. These increases led to $815 million incremental added costs for U.S. payers.
Related News Articles
Headline
The White House released a health care plan Jan. 15 addressing drug prices, health insurance premiums and price transparency efforts. The plan includes…
Headline
U.S. health care spending reached $5.3 trillion in 2024 — growing 7.2% from 2023 — the Centers for Medicare & Medicaid Services reported Jan. 14 in Health…
Headline
The 1st U.S. Circuit Court of Appeals Jan. 7 denied the government’s motion for a stay in a lawsuit filed by the AHA, the Maine Hospital Association and four…
Headline
The Department of Health and Human Services and Drug Enforcement Administration Dec. 30 released a temporary rule extending for the fourth time waiver…
Headline
The Centers for Medicare & Medicaid Services Dec. 23 introduced a new drug pricing model for Medicare Part D and Medicaid beneficiaries. The Better…
Headline
The Centers for Medicare & Medicaid Services Dec. 19 issued two proposed rules for implementing alternative drug pricing models. The first proposed…